PTO/SB/08a (08-03)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

	e for form 1449A/PTO	•		Complete if Known			
				Application Number	10/791,270		
I	NFORMATION D	ISCLOS	URE	Filing Date	March 3, 2004		
	STATEMENT BY	APPLIC/	ANT	First Named Inventor	Masaaki NOMURA		
				Art Unit	1615		
(use as many sheets as necessary)				Examiner Name	-(To Be Assigned) MEANS, AHMEN		
Sheet	1	of	1	Attorney Docket Number	100598.53322US		

			U.S. PATENT I	OCUMENTS	
Examiner Initials'	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
_300	AA	US- 03/0124188 A1	07/03/2003	Burnside et ai.	
Alex	AB	US-2001/0051188 A1	12-13-2001	Ullah et al.	
		US-			
	ļ	US-			

			FOREIG	N PATENT DO	CUMENTS		
	miner	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ¹ (il known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁰
4	HO .	AC	WO 00/76520 A1	12-21-2000	Hanmi Pharm Co., Ltd.		
	~	AD	WO 00/59475 A1	10-12-2000	Lipocine, Inc.		
		AE	WO 99/44614 A1	09-10-1999	DaeWoong Pharmaceutical Co., Ltd.		
	T	AF	DE 101 44 557 A1	03-27-2003	Bayer AG		
	7	AG	WO 03/037379 A1	05-08-2003	Degussa AG		
A	B)	AH	EP 0 722 732 A1	07-24-1996	Mitsui Toatsu Chemicals, Inc.		

	<u> </u>	
Examiner	Date	11 October 2007
Signature	Consi	deleg (1 - Compression)

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08a (08-03) Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

. Complete If Known Substitute for form 1449A/PTO 10/791,270 **Application Number** INFORMATION DISCLOSURE March 3, 2004 Filing Date Masaaki NOMURA First Named Inventor STATEMENT BY APPLICANT 1615 Art Unit HARAN S. AHORD 100598.53322US **Examiner Name** (use as many sheets as necessary) Attorney Docket Number Sheet of

			FOREIGN PATE	NT DOCUMENTS				
Examiner	Cite	Foreign Patent Document Country Code ³ –Number ⁴ –Kind Code ³	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Τ ⁰		
APA)	No.1	(If known) JP-61186314-A	08-20-1986	NIPPON ERANKO KK		AB		
1	AB	JP-07252138-A	10-03-1995	NIPPON ERANKO KK		AB		
	AC	JP-06072862-A	03-15-1994	NIPPON ERANKO KK		AB		
1	AD	JP-2552937-B2	08-22-1996	NIPPON ERANKO KK		AB		
++	AE	JP-2000202003-A	07-25-2000	SHIONOGI QUALICAPS KK		AB		
	AF	JP-08099869-A	04-16-1996	SHIONOGI & CO LTD		AB		
	AG	JP-2000026282-A	01-25-2000	SHIONOGI & CO LTD		AB		
1	AH	JP-61207387-A	09-13-1986	SUNTORY LTD		AB		
	Al	JP-63162694-A	07-06-1988	SUNTORY LTD		AB		
1	AJ	JP-60222486-A	11-07-1985	BRISTOL MYERS CO		AB		
	AK	JP-54119486-A	09-17-1979	CIBA GEIGY AG		AB		
₩/	AL	JP-06072875-A	03-15-1994	SUNTORY LTD		AB		
4A)	AM	JP-06128267-A	05-10-1994	SUNTORY LTD		AB		
		4 1	NON PATENT LITE	RATURE DOCUMENTS		,		
Examiner Initials*	Cite No.1	Include name of the author (in CA journal, serial, symposium, cat	APITAL LETTERS), ti alog, etc.), date, page	tle of the article (when appropriate), title of the a(s), volume-issue number(s), publisher, city published.	ne item (book, magazine, and/or country where	T²		
\$100	AN	TOSHIHIRO OGURA ET AL., "	New Cellulose Cap	osules" <i>Pharm. Tech.</i> (1988) pp. 67-76,	14(3).	Partial		
7	AO	The 32 nd Annual Conference of Pharmaceutics, Research Round-Table, Lecture Summery (1995) pp. 46-49.						
1	AP	The 8 th Symposium of the Society of Prescription of Solid Drug Product; Lecture Summery (1998), pp. 61-68.						
	AQ	YUICHIRO ITO ET AL., Antibio				Partial		
AR Textbook of Pharmaceutics, Revised 2 nd Edition, Ch. 7-1, pp 311-318, Japan.								
AS Japan Drug Excipient Dictionary 2000, Japan Pharmaceutical Excipients Council (8 pages)						Partial		
Examine Signatur		111)	Date Considered)CTOBER 2007			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.97 and 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO). to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14.